Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
Joint Authors
Liu, Ying
Ye, Zhengbao
Xi, Wenqi
Ma, Tao
Shi, Min
Yang, Liu
Zhu, Zhenggang
Zhang, Jun
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-09-15
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma.
Methods.
A total of 37 patients were enrolled into this study, and they received DOX regimen (docetaxel 75 mg/m2 and oxaliplatin 130 mg/m2 intravenous infusion on day 1, and capecitabine 1000 mg/m2 orally twice daily on d1–14); treatment was repeated every 3 weeks.
Results.
All 37 patients were assessable for evaluation.
The numbers of patients with complete response (CR), partial responses (PR), stable disease (SD), and progressive disease (PD) were 1, 10, 23, and 3, respectively.
The objective response rate (ORR) was 29.7%, with the disease control rate (DCR) of 91.9%.
Median progression-free survival (mPFS) and overall survival (mOS) were 197 days and 364 days, respectively.
The most common grade 3/4 toxicities were hematological toxicities.
The most common grade 3/4 nonhematological toxicities were fatigue, nausea, vomiting, anorexia, diarrhea, and hand-foot syndrome.
Conclusion.
The DOX regimen demonstrated a promising efficacy as the first line regimen in treating advanced gastric cancer patients with good performance status, the toxicities were tolerated and controllable.
Large-scale clinical observation is necessary to get further evidence.
American Psychological Association (APA)
Liu, Ying& Ye, Zhengbao& Xi, Wenqi& Ma, Tao& Shi, Min& Yang, Liu…[et al.]. 2013. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
Modern Language Association (MLA)
Liu, Ying…[et al.]. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
American Medical Association (AMA)
Liu, Ying& Ye, Zhengbao& Xi, Wenqi& Ma, Tao& Shi, Min& Yang, Liu…[et al.]. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1005542